HER2 testing in gastric/gastroesophageal junction adenocarcinomas: Unique features of a familiar test

Gastrointestinal Cancer Research

Volumn 4, Issue 2, 2011, Pages 62-66

  Ross, Jeffrey S ^a   Mulcahy, Mary ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; TRASTUZUMAB;

ADD ON THERAPY; ARTICLE; BREAST CANCER; DRUG APPROVAL; DRUG INDICATION; DRUG RESPONSE; ESOPHAGEAL ADENOCARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY; LOWER ESOPHAGUS SPHINCTER ADENOCARCINOMA; OVERALL SURVIVAL; PATHOLOGIST; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; SCREENING; STOMACH ADENOCARCINOMA; UNITED STATES;

EID: 80053018463     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. Cancer J Clin 60:277-300
2. Shah MA, Kelsen DP: Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw 8:437-447
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006
4. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46, 2008
5. Ross JS, Slodkowska EA, Symmans WF, et al: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320-368, 2009
6. Ross JS, McKenna BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19:554-568, 2001
7. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
8. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805, 2008
9. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
10. Bang Y CH, Xu J: Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 27:15s, 2009 (suppl; abstr 4556)